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Invariant natural killer T (iNKT) cells are implicated in the pathogenesis of several dis-
eases. They inﬂuence both innate and adaptive immune responses through their capacity
to rapidly produce large quantities of cytokines upon activation. During pregnancy mater-
nal immunity is biased towards type 2 cytokine production to regulate type 1 cytokines that
could be harmful for the developing fetus. This shift to type 2 cytokines does not occur in
preeclamptic women and there is an exaggerated maternal inﬂammatory response which
is dangerous for both mother and baby. We have therefore investigated the numbers, phe-NKT cells
uman pregnancy
reeclampsia
notype and functional activity of iNKT cells throughout pregnancy and inwomendiagnosed
with preeclampsia. We demonstrate that the numbers of iNKT cells in the peripheral blood
do not change between the ﬁrst, second and third trimesters of pregnancy, but the cells
become activated and less able to produce the type 1 cytokine IFN. However, iNKT cells
are unchanged in preeclamptic women, when compared to normal pregnancy, suggesting
not pr
 that these cells are
. Introduction
During pregnancy, the maternal immune system is
odiﬁed to enable survival of the semi-allogeneic fetus. It
as originally proposed that type 2 cytokines (e.g. IL-4, IL-
, IL-6, IL-10) are prevalent, and type 1 cytokines (e.g. IFN,
L-2, IL-12, TNF and TNF) are diminished, to prevent
he activation of cell mediated immunity and inﬂamma-
ion (Wegmann et al., 1993). However, the ﬁnding that
regnancy itself is an inﬂammatory state has led to a revi-
ion of this hypothesis and it is now apparent that both
rms of the immune response are intensiﬁed, but with a
tronger bias towards type 2 than type 1 responses in suc-
essful pregnancy (Redman and Sargent, 2003; Chaouat et
l., 2007). The causes behind this cytokine shift are not
∗ Corresponding author at: Nufﬁeld Department of Obstetrics and
ynaecology, Level 3, Women’s Centre, John Radcliffe Hospital, Oxford
X3 9DU, UK. Tel.: +44 1865 221017; fax: +44 1865 769141.
E-mail address: jen.southcombe@obs-gyn.ox.ac.uk (J. Southcombe).
165-0378 © 2010 Elsevier Ireland Ltd. 
oi:10.1016/j.jri.2010.07.003
Open access under CC BY license. imary players in the pathogenesis of the disease.
© 2010 Elsevier Ireland Ltd. 
clearly deﬁned, but it is known that the placenta produces
type 2 cytokines such as IL-4 and IL-10, as well as pro-
gesterone (Sacks et al., 2001; Szekeres-Bartho et al., 2009),
whichmay inﬂuencematernal immunity (DeMoraes-Pinto
et al., 1997; Chaouat et al., 1999).
Preeclampsia is the most common medical compli-
cation of pregnancy affecting 3–5% of all pregnancies.
The maternal syndrome is characterised by new-onset
hypertension and proteinuria which are caused by the
excessive release of placenta derived factors into the blood.
These factors stimulate an exaggerated maternal systemic
inﬂammatory response of which endothelial dysfunction
is a part (Redman and Sargent, 2009). In preeclampsia, the
shift away from type 1 responses either fails to occur or
is reversed, with increased production of IL-18 and IFN
relative to normal pregnancy (Germain et al., 2007). This
Open access under CC BY license.type 1 bias can be seen in T cells (Saito et al., 2007) and
morepredominantly inNKandNKT-like (CD3+CD56+) cells
(Borzychowski et al., 2005). The latter cell type are of par-
ticular interest as recently a speciﬁc subset of invariant
natural killer T cells (iNKT) has been deﬁned, which link
productJ. Southcombe et al. / Journal of Re
innate and adaptive immune responses (Matsuda et al.,
2008).
iNKT cells are a unique population that express an
invariant T cell receptor (TCR), comprised of V11 and
V24 chains (Porcelli et al., 1993; Prussin and Foster,
1997). They also share characteristics with NK cells, in that
they are cytotoxic through the action of granzymes and
perforins, and are potent producers of a wide variety of
cytokines (Crowe et al., 2003; Van Kaer, 2004). iNKT cells
are important regulators of host defence in microbial and
viral infections (Bendelac et al., 2007), and are involved
with the development or progression of a range of con-
ditions, such as cancer, autoimmunity or allergy (Godfrey
and Kronenberg, 2004).
iNKT cells recognise and are activated by endoge-
nous or exogenous lipid ligands presented by the major
histocompatibility complex class I-like molecule, CD1d,
on antigen presenting cells (Barral and Brenner, 2007).
They can be activated using a pharmacological agent;
-galactosylceramide (-galcer) which is based on a gly-
cosphingolipid isolated from the marine sponge Agelas
mauritianus, and has antitumour activity in the mouse B16
melanomamodel (Morita et al., 1995; Kawano et al., 1997).
Activation with -galcer leads to the release of both type 1
and type 2 cytokines and the secondary activation of T cells,
B cells and NK cells. The capacity of iNKT cells to produce
cytokines can be deﬁned by their differential expression of
CD4andCD8. CD4+ iNKT cells have a Th0 cytokine response
in that they produce both type 1 and type 2 cytokines, CD8+
iNKT are primarily type 1 cytokine producers and double
negative (CD4−/CD8−) iNKT produce type 1 cytokines but
only low levels of IL-4 (Exley et al., 1997; Takahashi et al.,
2000;Gumperzet al., 2002;Kimetal., 2002; Leeet al., 2002;
Takahashi et al., 2002).
Several observations suggest that iNKT cells may play a
key role in pregnancy and preeclampsia. First, treatment of
pregnantmicewith a-galcer results in abortion due to iNKT
IFN- release (Ito et al., 2000;Boysonet al., 2006). Secondly,
iNKT cells play a role in priming Th2 immune responses
(Prussin and Foster, 1997; Singh et al., 1999). Thirdly, iNKT
cells regulate NK cell activation and proliferation (Carnaud
et al., 1999; Eberl and Macdonald, 2000; Metelitsa et al.,
2001), cells that are known to be critical for the progression
and success of pregnancy.
Wehave therefore investigated the absolute count, phe-
notype (CD4, CD8 and CD69 expression) and functional
activity (IFN production) of iNKT cells in each trimester
of pregnancy and in matched trios of non-pregnant, nor-
mal pregnant and preeclamptic women. Our aim was to
determine whether there are changes in iNKT cells asso-
ciated with pregnancy, and if so, how they might differ in
preeclampsia.
2. Methods
2.1. SubjectsTo study iNKT cells throughout pregnancy, 15 healthy
women were recruited in the ﬁrst trimester, and subse-
quent samples were taken during the second and third
trimesters (Table 1). Themean age of thewomenwas 31.27ive Immunology 87 (2010) 52–59 53
(±4.17) years and 40% were nulliparous. Of the women
recruited for this study, two developed preeclampsia later
in pregnancy but had normal blood pressure at the time of
each sample.Data for these twowomenwas included in the
study, removing the data did not alter the results. Nineteen
preeclamptic women were recruited who presented with
≥90mmHg diastolic BP on at least two occasions within
24h and proteinuria ≥500mg in a 24-h protein urine col-
lection, 50mg/mmol protein/creatinine ratio or at least
2+ on dipstick testing on two consecutive measurements.
Preeclamptic women (15 primiparous and 4 multiparous
women) were recruited and matched to 19 non-pregnant
women for age (± 4 years) and parity (0, 1–3, 4+), and
to 19 normal pregnant women for age, parity and ges-
tational age (±13 days) (Table 2). All cases and controls
were not in labour at the time of sampling, and had sin-
gleton pregnancies, with no known fetal abnormalities. All
control pregnancies progressed normally to term. None of
the women had any signiﬁcant medical history, current or
recent illnesses, orwere takingmedication (excluding con-
traceptives in the non-pregnant group). These studieswere
approved by the Oxfordshire Research Ethics Committee C.
2.2. Blood collection
Blood samples (20–30ml) were collected into sodium
heparin anti-coagulant (10U/ml) and peripheral blood
mononuclear cells (PBMC) were prepared by density
gradient centrifugationover lymphoprep (Axis ShieldDiag-
nostics, Cambridgeshire,UK). Cellswerewashed twicewith
PBS/1% FCS and consecutive centrifugation of 800g and
200× g×10min, then used immediately for ﬂow cytom-
etry while the remainder were re-suspended in 10% DMSO
in FCS and cryopreserved in liquid nitrogen.
2.3. Flow cytometry
The concentrations of T cells and PBMC were deter-
mined by ﬂow cytometry using Cytognos absolute count
beads (Caltag-MedSystems, Buckingham, UK). Whole
blood (50l) was incubated with CD3-PeCy5 antibodies
(eBiosciences, San Diego, USA) for 15min then the red
blood cells were lysed with FACS Lysing Solution (Becton
Dickinson, Oxford, UK) for 15min. Absolute count beads
(50l) were added and the number of PBMC or CD3+ve
T cells per ml blood was calculated relative to the beads.
iNKT cells were identiﬁed using six-colour ﬂow cytometry.
Antibodies used were FITC anti-human TCR V11 and PE
anti-human TCR V24 (Beckman Coulter, High Wycombe,
UK), PeCy5-anti-human CD3 (Biolegend, San Diego, USA),
PeCy7anti-humanCD8 (eBioscience, SanDiego,USA), and
APC anti-human CD69 and APC anti-human CD4 (Becton
Dickinson, Oxford, UK).
PBMC (2×106) were incubated with the six antibodies
for 20min at 4 ◦C in the dark, then washed twice with 1ml
PBS/1%FCS andbrief centrifugation at 10,000× g×5 s. Cells
were resuspended in 1ml PBS/1% FCS and at least 1million
events were acquired immediately on the ﬂow cytometer
(Becton Dickinson LSR II). Compensation was determined
using FACS compensationbeads (BectonDickinson,Oxford,
UK) and gates drawn using Fluorescence Minus One gat-
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Table 1
Patient data for the longitudinal study. Data are shown as mean (± standard deviation).
1st trimester 2nd trimester 3rd trimester
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PGestation (weeks) 12.35 (1.00)
Booking bp, mmHg 111/68 (15.56/8.18)
Birthweight –
ng (Roederer, 2002). iNKT cells within the PBMC gate
ere identiﬁed as CD3+V24+V11+ events. The percent-
ge of iNKT cellswithin theCD3+ve gatewas calculated and
elated to the known absolute count of CD3+ve cells perml
f blood to determine the iNKT cell absolute count. Data
as analysed using FACSDIVA software (Becton Dickinson,
xford, UK).
.4. Measurement of iNKT cell IFN production by
LISPOT
IFN production by iNKT cells was measured using an
LISPOT assay (Mabtech, Sweden). PBMC were thawed
nd cultured for 24h in human serum media (RPMI
640 supplemented with 10% human serum (Sera
aboratories International,West Sussex, UK), 1% penicillin-
treptomycin (50 IU/ml and 50g/ml), 1% glutamine,MEM
EAA, sodium pyruvate and 50nM 2-mercaptoethanol
Gibco Invitrogen, Paisley, UK)), supplemented with
00U/ml IL-2 (Chiron, California, USA). Freezing did not
ffect the number of responsive iNKT cells (data not
hown). Live cells were then counted using trypan blue
taining and 5×105 PBMC added per well to the ELISPOT
lates in the presence or absence of 100ng/ml -galcer
Proimmune, Oxford, UK). 104 cells per well were incu-
ated with 1:100 dilution of phytohemagglutinin (Sigma,
t. Louis, USA) as a positive control. Cells were incu-
ated overnight and IFN producing cells were detected as
escribed in the manufacturer’s instructions. Spots were
ounted using an AID ELISPOT plate reader (Autoimmun
iagnostika GmbH, Strassberg, Germany), and spots were
nalysed using AID Software. Numbers of iNKT cells per
×105 PBMC were determined from the ﬂow cytome-
ry analysis, and therefore percentages of responding iNKT
ells were calculated. Each experiment was performed in
riplicate (n=3).
able 2
atient details for matched groups of non-pregnant, normal pregnant and preecla
Non-pregnant
Age (years) 30.63 (5.55)
Nulliparous 79%
Gestation (weeks) –
Booking bp, mmHg –
Max bp, mmHg –
Max proteinuria, mg/24h –
Birthweight –21.70 (1.85) 35.70 (1.24)
– –
– 3585.80 (478.95)
2.5. Statistical analysis
For the longitudinal study of CD69 expression levels
on iNKT cells, Gaussian distribution was conﬁrmed by a
Shapiro–Wilk test, and signiﬁcance values calculated by
ANOVAwith a Newman–Kewls post test, ‘*’ is p<0.01. Data
for iNKT IFN production was non-parametric and there-
fore aWilcoxon test was performed for statistical analysis,
*p<0.05 and **p<0.005. Signiﬁcant differences between
maximum blood pressure and birthweight between the
preeclamptic and normal pregnant women were detected
using aWilcoxonmatched pairs test (ns – non-signiﬁcant).
3. Results
3.1. iNKT cell numbers and phenotype throughout
pregnancy
Six colour ﬂow cytometry was used to study iNKT cells
in the peripheral blood of normal pregnant women dur-
ing each trimester of pregnancy. A representative example
of the data acquired can be seen in Fig. 1. Lymphocytes
were gated on forward and side scatter (Fig. 1(A)), CD3+ve
T cells were gated (Fig. 1(B)) and iNKT cells were identiﬁed
as CD3+V24+V11+ cells within the lymphocyte popula-
tion (Fig. 1(C)). iNKT expression of CD4 and CD8 (Fig. 1(D))
and CD69, an early T cell activation marker (Fig. 1(E)), was
also analysed.
The absolute count of iNKT cells per ml of blood
remained constant throughout pregnancy (Fig. 2(A)) as did
the relative numbers of iNKT cells measured as a propor-
tion of the T cells (Fig. 2(B)). Percentages of CD4+ve, CD8+ve
and CD4−ve/CD8−ve (double negative – DN) iNKT did not
alter signiﬁcantly throughout pregnancy (Fig. 2(C)–(E)).
CD69 expression (measured as the increase of median
ﬂuorescence intensity) on the total iNKT cell population
was slightly increased in the third trimester but this was
mptic women (n=19). Data are shown as mean (± standard deviation).
Normal pregnant Preeclamptic
29.42 (4.29) 30.05 (5.02)
ns
79% 79%
ns
35.17 (3.59) 35.82 (3.25)
ns
110/65 (10.28/6.96) 115/68 (11.31/10.27)
ns
133/78 (13.05/11.01) 164/104 (14.22/7.90)
p<0.0005
– 2911.36 (3131.62)
Range 525–12,801
3437.71 (453.42) 2672.32 (868.43)
p<0.05
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Fig. 1. Representative ﬂow cytometry analysis. PBMC were isolated by lymphoprep density preparation then stained with antibodies for ﬂow cytometry.
Live PBMCwere identiﬁed by FSC vs. SSC (A) and iNKT cells were CD3 positive (B) and V24 and V11 positive (C). Expression of CD4 and CD8 (D) and CD69
expression (E) was detected. For simplicity, the ﬁgure shows CD69 expression on the whole iNKT cell population however in the study CD69 expression
was determined on each of the CD4+CD8−, CD4−/CD8+ and double negative populations.
Fig. 2. Enumeration and phenotyping of iNKT throughout pregnancy. Flow cytometry determination of the numbers and phenotype of iNKT cells in the
peripheral blood of pregnant women, in the ﬁrst, second and third trimesters of pregnancy. iNKT cells were classiﬁed as CD3+V24+V11+ cells. Absolute
counts of iNKT cells (A) were determined by calculating the number of CD3+ T cells in a whole blood sample, then the proportion of iNKT cells per CD3+ T
cells on PBMC prepared by density centrifugation (B) was calculated and this value related to the whole blood T cell count. Antibodies towards CD4 or CD8
identiﬁed CD4+ (C), CD4−CD8− DN (D) or CD8+ (E) iNKT cells. Bars represent mean values.
56 J. Southcombe et al. / Journal of Reproductive Immunology 87 (2010) 52–59
F lowcyt
i C) or CD
n
s
n
c
(
p
3
t
t
c
d
p
i
a
3
s
n
s
p
p
a
iig. 3. Expressionof theactivationmarkerCD69by iNKTcell populations. F
ntensity) on the total iNKT cell population (A), CD4+ iNKT (B), DN iNKT (
ot statistically signiﬁcant (Fig. 3(A)). However, when the
ubgroups of cellswere analysed, CD69 expressionwas sig-
iﬁcantly increasedon theCD4−ve/CD8−veandCD8+ iNKT
ells during the third trimester of pregnancy (Fig. 3(C) and
D)). No changes in thismarkerwere seenon theCD4+ iNKT
opulation (Fig. 3(B)).
.2. IFN production by iNKT cells throughout pregnancy
The percentage of iNKT cells producing IFN during
he second trimester of pregnancy was signiﬁcantly lower
han in the ﬁrst trimester (Fig. 4(A)). The number of iNKT
ells per ml of blood producing IFNwas also signiﬁcantly
ecreased during the second and third trimesters com-
ared to the ﬁrst (Fig. 4(B)). A similar signiﬁcant decrease
n IFN productionwas seen in PBMC stimulatedwith PHA,
s a positive control (Fig. 4(C)).
.3. iNKT cell numbers and phenotype in preeclampsia
The numbers and phenotype of iNKT cells were mea-
ured in preeclamptic women compared to matched
ormal pregnant and non-pregnant controls. There was no
igniﬁcant difference in the absolute count of iNKT cells
erml of blood or the percentages of iNKT cells in the T cell
opulation between the three groups of women (Fig. 5(A)
nd (B)). Similarly, therewasno change in theproportionof
NKT cells expressing CD4or CD8between the three groupsometrywasused tocalculate theexpressionofCD69 (medianﬂuorescence
8+ iNKT (D). Bars represent median values.
(Fig. 5(C)–(E)). iNKT cell expression of the early activation
marker CD69 was unchanged between the three groups
as a whole (Fig. 6(A)) or within each CD4/DN/CD8 subset
(Fig. 6(B)–(D)).
3.4. IFN production by iNKT cells in preeclampsia
Therewasa slight reduction in thenumbersof iNKTcells
producing IFN in normal pregnant women compared to
women with preeclampsia and the non-pregnant controls
but this was not statistically signiﬁcant (Fig. 6(E)).
4. Discussion
Changes in iNKT cell numbers, phenotype and func-
tion are associated with progression of various diseases,
for example in allergies such as asthma (Matangkasombut
et al., 2009), autoimmunities such as systemic lupus ery-
thematosus (Gabriel et al., 2009) and cancer (Molling et al.,
2008), often with associated cytokine imbalance. The abil-
ity of iNKT cells to drive and modulate immune responses
makes them attractive candidates for being key regulators
of immunity during pregnancy. Boyson et al. have previ-
ously shown that iNKT cells are present in ﬁrst trimester
(7–10 weeks) decidua at a frequency 10 times greater than
seen in peripheral blood (Boyson et al., 2002). It is possi-
ble that they interact with CD1d expressed on the invasive
extravillous cytotrophoblast. Interestingly CD4+ve decid-
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les were
NKT cel
spond to
n test wFig. 4. IFN production by iNKT cells in response to -galcer. PBMC samp
assay. Known numbers of PBMC were added per well and the number of i
number of iNKT cell per 106 PBMC therefore the % of iNKT cells able to re
a positive control (C). The data is non-parametric and therefore a Wilcoxo
ual iNKT cell clones stimulated with CD1d transfected C1R
cells (a MHC class I negative EBV transformed B cell line)
pulsed with -galcer showed a strong bias to IFN (type
1) production compared to peripheral blood iNKT clones
which were biased to IL-4 production (type 2).
In this study we focussed on iNKT cells in peripheral
blood as our aim is to study their role in the maternal
Fig. 5. Enumeration and phenotype of iNKT cells in non-pregnant, normal preg
iNKT cells in the T cell population (B) was determined by ﬂow cytometry. Antibod
(E) iNKT cells. Bars represent mean values.treated with 100ng/ml -galcer and IFN released detected by ELISPOT
ls responding per 106 PBMC calculated (A). Flow cytometry identiﬁed the
-galcer was calculated (B). PBMC responses to PHA was determined as
as performed for statistical analysis, *p<0.05 and **p<0.005.
syndrome of preeclampsia which is a maternal systemic
inﬂammatory disorder of the second half of pregnancy.We
ﬁrst investigated iNKT cells during each trimester of preg-
nancy, and found that while the number and type of iNKT
cells do not change, the cells become activated, as demon-
strated by increased CD69 expression on CD4−ve/CD8−ve
and CD8+ iNKT cells during the third trimester. IFN pro-
nant and preeclamptic women. The absolute count (A) or proportion of
ies towards CD4 or CD8 identiﬁed CD4+ (C), CD4−CD8− DN (D) or CD8+
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esponse to -galcer was determined by ELISPOT as previously described
uction is reduced, which is consistent with previous
bservations showing a shift to a type 2 phenotype on NK
nd NKT-like cells (Borzychowski et al., 2005) and a type 2
ias in cytokine production in pregnancy (Germain et al.,
007). This data suggests that iNKT cells contribute to this
ytokine bias. We were unable to measure the concomi-
ant production of IL-4 due to ethical limitations on the
olume of bloodwewere able to take for these studies, but
rom the results of Boyson et al. it might be expected that
n increase in IL-4 production by iNKT cells would also be
een later in pregnancy. The increased activation of CD4
egative cells, typically type 1 cytokine producers, is para-
oxical, andmay represent a portion of cells that have been
ctivated but have become anergic in response to chronic
timulation invivo, a featureof activatedhumanandmouse
NKT cells after long term exposure to -galcer (Sullivan
nd Kronenberg, 2005).
From the above results it might be expected that
NKT cells could play an important role in preeclamp-
ia where increased IFN production by PBMC is seen
ompared to normal pregnancy (Germain et al., 2007).
owever, no differences in iNKT cell number or pheno-
ype were seen between women with preeclampsia and
heir matched normal pregnant and non-pregnant con-
rols. A slight decrease in iNKT cell production of IFN
as seen in normal pregnant compared to preeclamptic
omen, but this was not statistically signiﬁcant. There has
een one previous study of peripheral blood iNKT cells in
reeclampsia (Miko et al., 2008). In contrast to our study,
t was found that the percentage of activated (CD69+ve)
NKT cells was signiﬁcantly higher in preeclampsia com-
ared to the matched normal pregnant and non-pregnant
ontrols aswas thepercentageof iNKT cells producing IFN
as determined by intracellular cytokine staining). They didtic women. Flow cytometry was used to calculate the expression of CD69
T (B), DN iNKT (C) or CD8+ iNKT (D). IFN- production by iNKT cells in
producing IFN- (E).
not investigate iNKT cells at other stages of gestation. The
differences in results between the studies may be due to
differences in the methodology. Miko et al. stained 50l
whole blood for the iNKT TCR using the 6B11 antibody
(Montoya et al., 2007), and analysed at least 1000 iNKT
cells, i.e. greater than 20,000 cells/ml, which is very high
for iNKT cells. Our data are more consistent with other
reports, for example Molling et al. (2005) who show an
average of approximately 1000 iNKT/ml blood at 30 years
age; our patients had a range of just 46 to 14,563 iNKT
cells/ml blood. Miko et al. gated their lymphocytes on for-
ward and side scatter only rather than using CD3 staining
as in our study, which could have lead to the inclusion of
false positive events in their analysis.
In summary, we show evidence for activation of
iNKT cells and a decrease in IFN production as preg-
nancy progresses. However, no signiﬁcant changes in
CD69 expression or IFN production were seen between
preeclamptic andnormalpregnantwomen, suggesting that
iNKT cells are not amajor player in the pathogenesis of this
condition.
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